• Cy5 Goat Anti-Mouse IgG (H+L) Guide

  2026-09-29

  This scenario-driven guide explains how Cy5 Goat Anti-Mouse IgG (H+L) Antibody, SKU K1210, can improve mouse IgG detection in immunocytochemistry, immunohistochemistry, and flow cytometry workflows. It emphasizes controls, optimization, storage, interpretation, and practical vendor-selection criteria for cell viability, proliferation, and cytotoxicity studies.

• CELLFIE Reveals CRISPR-Boosted CAR T Cell Design

  2026-09-28

  The reference study introduces CELLFIE, a high-content CRISPR screening platform designed to identify genetic perturbations that improve CAR T cell performance across clinically relevant failure modes. Genome-wide, in vivo, combinatorial, and base-editing experiments highlighted RHOG, PRDM1, and FAS, with RHOG disruption—especially alongside FAS loss—emerging as a notable strategy for enhancing antitumour activity.

• DAPI (hydrochloride) for Host–Pathogen Assays

  2026-09-28

  Learn how to use DAPI (hydrochloride) to visualize and quantify DNA in cell-based studies inspired by erythrocyte-mimicking nanovesicle research on periodontitis. The guide separates what the published study demonstrated from practical staining workflows, with starting conditions and troubleshooting for imaging and flow cytometry.

• Adenosine Triphosphate for Mitochondrial Metabolism

  2026-09-27

  Use ATP as a carefully controlled reagent to connect mitochondrial metabolic changes with cellular energy readouts—without mistaking a bulk ATP measurement for a specific OGDH assay. This workflow pairs practical ATP handling with the 2025 discovery that TCAIM can lower OGDH protein levels through mitochondrial proteostasis.

• 2-NBDG Glucose Uptake Assay Kit: Research Guide

  2026-09-26

  The 2-NBDG Glucose Uptake Assay Kit measures cellular accumulation of a fluorescent glucose analogue without radioactivity. It can complement, but does not reproduce, the lipid-metabolism and ferroptosis analyses reported in the 2024 HCC sorafenib-resistance study.

• HNF4A-AS1, Lipid Metabolism, and Sorafenib Resistance

  2026-09-25

  A 2024 study links low HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through METTL3-dependent m6A modification of DECR1 mRNA, reduced PUFA abundance, and weaker ferroptosis. Its combined cell, organoid, xenograft, and molecular analyses provide a mechanistic framework for studying lipid-metabolism-driven treatment response, while leaving clinical validation as an important next step.

• G-1 for GPR30 Immune and Cardiac Assays

  2026-09-25

  Use G-1 to isolate rapid GPR30 signaling from classical estrogen-receptor effects, then connect receptor activation to functional immune, migration, or cardiac readouts. This guide pairs the hemorrhagic-shock immune workflow with practical controls, compound-handling advice, and clear limits on transferring results between models.

• 740 Y-P: Practical PI 3-Kinase Activation

  2026-09-24

  740 Y-P is a PI 3-kinase activator for researchers testing PI3K/AKT pathway responses, including vesicular trafficking, cell survival, and cancer research models. Use it as an experimental perturbation with matched vehicle and endpoint controls; do not treat dossier examples as a universally validated dose or as evidence of clinical effect.

• Sildenafil Citrate: From cGMP to Assay Design

  2026-09-24

  Sildenafil Citrate is more than a cGMP-pathway probe: its effects can depend on the biological context and the assay used to measure them. Learn how to connect PDE5 inhibition, downstream signaling, and proteoform-aware target engagement without overinterpreting experimental results.

• MLN8237 (Alisertib): Practical Aurora A Workflows

  2026-09-23

  Use MLN8237 (Alisertib) to test how Aurora A activity shapes mitosis, survival, and tumor-cell responses—not simply to generate a viability value. This guide turns retinoblastoma findings into a staged workflow with practical controls, dose-and-time optimization, and troubleshooting for preclinical cancer biology.

• ATP Quality and mRNA Therapy Translation

  2026-09-23

  The emerging p21 mRNA–LNP strategy for localized bladder cancer therapy illustrates how transient gene expression can become a translationally relevant treatment concept. This article connects that biology to the upstream ATP-dependent workflows that determine the reproducibility of in vitro transcription, kinase, ligation, and phosphorylation studies.

• PSI-7977 in Reproducible Cell Assays

  2026-09-22

  Learn how to evaluate PSI-7977 (SKU A3738) in cell viability, proliferation, and cytotoxicity workflows without confusing assay signal with mechanism. This scenario-based guide combines practical plate design, pathway-aware controls, vendor selection, and evidence from disulfidptosis research.

• LY2603618: From Checkpoint Biology to Translation

  2026-09-22

  A mechanistic and translational perspective on LY2603618 as a selective Chk1 inhibitor, with practical guidance for DNA damage assays, chemotherapy-sensitization studies, biomarker strategy, and iPSC-informed prescreening.

• LY2603618: Chk1 Control of Genome Stress

  2026-09-21

  LY2603618 is a selective Chk1 inhibitor for dissecting checkpoint failure, DNA damage, and chemotherapy response. This article connects Chk1 perturbation with nuclear cGAS–TRIM41 genome surveillance to define more informative assay strategies.

• BML-277 for Reliable Chk2 Assays

  2026-09-21

  Learn how BML-277 (SKU B1236) can support reproducible Chk2 inhibition, T-cell radioprotection studies, and DNA damage response research. This scenario-based guide covers assay design, solvent handling, dose interpretation, literature integration, and practical vendor selection.

8101 records 1/541 page Next 12345 下5页 Last page